Literature DB >> 30911118

Targeting natural killer cells in solid tumors.

Guillaume Habif1, Adeline Crinier2, Pascale André1, Eric Vivier1,2,3, Emilie Narni-Mancinelli4.   

Abstract

Natural killer (NK) cells are innate lymphoid cells endowed with cytolytic activity and a capacity to secrete cytokines and chemokines. Several lines of evidence suggest that NK cells play an important role in anti-tumor immunity. Some therapies against hematological malignacies make use of the immune properties of NK cells, such as their ability to kill residual leukemic blasts efficiently after conditioning during haploidentical hematopoietic stem cell transplantation. However, knowledge on NK cell infiltration and the status of NK cell responsiveness in solid tumors is limited so far. The pro-angiogenic role of the recently described NK cell-like type 1 innate lymphoid cells (ILC1s) and their phenotypic resemblance to NK cells are confounding factors that add a level of complexity, at least in mice. Here, we review the current knowledge on the presence and function of NK cells in solid tumors as well as the immunotherapeutic approaches designed to harness NK cell functions in these conditions, including those that aim to reinforce conventional anti-tumor therapies to increase the chances of successful treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30911118      PMCID: PMC6474204          DOI: 10.1038/s41423-019-0224-2

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  117 in total

Review 1.  SLAM family receptors in normal immunity and immune pathologies.

Authors:  Ning Wu; André Veillette
Journal:  Curr Opin Immunol       Date:  2015-12-02       Impact factor: 7.486

Review 2.  Surface NK receptors and their ligands on tumor cells.

Authors:  Lorenzo Moretta; Cristina Bottino; Daniela Pende; Roberta Castriconi; Maria Cristina Mingari; Alessandro Moretta
Journal:  Semin Immunol       Date:  2006-05-26       Impact factor: 11.130

Review 3.  Functions of natural killer cells.

Authors:  Eric Vivier; Elena Tomasello; Myriam Baratin; Thierry Walzer; Sophie Ugolini
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 4.  Receptors for HLA class-I molecules in human natural killer cells.

Authors:  A Moretta; C Bottino; M Vitale; D Pende; R Biassoni; M C Mingari; L Moretta
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 5.  Innate Lymphoid Cells: 10 Years On.

Authors:  Eric Vivier; David Artis; Marco Colonna; Andreas Diefenbach; James P Di Santo; Gérard Eberl; Shigeo Koyasu; Richard M Locksley; Andrew N J McKenzie; Reina E Mebius; Fiona Powrie; Hergen Spits
Journal:  Cell       Date:  2018-08-23       Impact factor: 41.582

Review 6.  Activation, coactivation, and costimulation of resting human natural killer cells.

Authors:  Yenan T Bryceson; Michael E March; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Immunol Rev       Date:  2006-12       Impact factor: 12.988

7.  Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.

Authors:  Yenan T Bryceson; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

8.  Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46.

Authors:  Thierry Walzer; Mathieu Bléry; Julie Chaix; Nicolas Fuseri; Lionel Chasson; Scott H Robbins; Sébastien Jaeger; Pascale André; Laurent Gauthier; Laurent Daniel; Karine Chemin; Yannis Morel; Marc Dalod; Jean Imbert; Michel Pierres; Alessandro Moretta; François Romagné; Eric Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

Review 9.  Organ-specific features of natural killer cells.

Authors:  Fu-Dong Shi; Hans-Gustaf Ljunggren; Antonio La Cava; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

Review 10.  Activating and inhibitory receptors expressed on innate lymphoid cells.

Authors:  Sophie Guia; Aurore Fenis; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Semin Immunopathol       Date:  2018-05-22       Impact factor: 11.759

View more
  68 in total

Review 1.  Second malignancies in multiple myeloma; emerging patterns and future directions.

Authors:  Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

Review 2.  Immunosenescence: a key player in cancer development.

Authors:  Jingyao Lian; Ying Yue; Weina Yu; Yi Zhang
Journal:  J Hematol Oncol       Date:  2020-11-10       Impact factor: 17.388

3.  IL-17 constrains natural killer cell activity by restraining IL-15-driven cell maturation via SOCS3.

Authors:  Xuefu Wang; Rui Sun; Xiaolei Hao; Zhe-Xiong Lian; Haiming Wei; Zhigang Tian
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-12       Impact factor: 11.205

Review 4.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

5.  Minimal PD-1 expression in mouse and human NK cells under diverse conditions.

Authors:  Sean J Judge; Cordelia Dunai; Ethan G Aguilar; Sarah C Vick; Ian R Sturgill; Lam T Khuat; Kevin M Stoffel; Jonathan Van Dyke; Dan L Longo; Morgan A Darrow; Stephen K Anderson; Bruce R Blazar; Arta M Monjazeb; Jonathan S Serody; Robert J Canter; William J Murphy
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 6.  Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.

Authors:  Heliang Li; Phei Er Saw; Erwei Song
Journal:  Cell Mol Immunol       Date:  2020-04-20       Impact factor: 11.530

7.  Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells.

Authors:  Muxin Yu; Hong Pan; Nan Che; Li Li; Cong Wang; Yue Wang; Ge Ma; Mengjia Qian; Jiawei Liu; Mingjie Zheng; Hui Xie; Lijun Ling; Yi Zhao; Xiaoxiang Guan; Qiang Ding; Wenbin Zhou; Shui Wang
Journal:  Cell Mol Immunol       Date:  2020-05-08       Impact factor: 11.530

8.  Combined immunodeficiency (CVID and CD4 lymphopenia) is associated with a high risk of malignancy among adults with primary immune deficiency

Authors:  R Shavit; R Maoz-Segal; S Frizinsky; S Haj-Yahia; I Offengenden; D Machnas-Mayan; Y Tunisky; M Iancovici-Kidon; N Agmon-Levin
Journal:  Clin Exp Immunol       Date:  2021-02-25       Impact factor: 4.330

Review 9.  The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Authors:  Xiaohu Zheng; Yaqi Wu; Jiacheng Bi; Yingying Huang; Ying Cheng; Yangyang Li; Yuwei Wu; Guoshuai Cao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 11.530

Review 10.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.